Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Cisplatin facilitates radiation-induced abscopal effects in conjunction with PD-1 checkpoint blockade through CXCR3/CXCL10-mediated T cell recruitment.

Luo R, Firat E, Gaedicke S, Guffart E, Watanabe T, Niedermann G.

Clin Cancer Res. 2019 Sep 10. pii: clincanres.1344.2019. doi: 10.1158/1078-0432.CCR-19-1344. [Epub ahead of print]

PMID:
31506388
2.

Author Correction: Radiotherapy toxicity.

De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.

Nat Rev Dis Primers. 2019 Mar 4;5(1):15. doi: 10.1038/s41572-019-0073-4.

PMID:
30833595
3.

Combination treatment with hypofractionated radiotherapy plus IL-2/anti-IL-2 complexes and its theranostic evaluation.

Jing H, Hettich M, Gaedicke S, Firat E, Bartholomä M, Niedermann G.

J Immunother Cancer. 2019 Feb 26;7(1):55. doi: 10.1186/s40425-019-0537-9.

4.

Radiotherapy toxicity.

De Ruysscher D, Niedermann G, Burnet NG, Siva S, Lee AWM, Hegi-Johnson F.

Nat Rev Dis Primers. 2019 Feb 21;5(1):13. doi: 10.1038/s41572-019-0064-5. Review. Erratum in: Nat Rev Dis Primers. 2019 Mar 4;5(1):15.

PMID:
30792503
5.

Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.

Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X.

Hum Gene Ther. 2019 Apr;30(4):446-458. doi: 10.1089/hum.2017.234. Epub 2018 Apr 27.

PMID:
29706119
6.

Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.

Zhang X, Niedermann G.

Int J Radiat Oncol Biol Phys. 2018 May 1;101(1):63-73. doi: 10.1016/j.ijrobp.2018.01.094. Epub 2018 Feb 3.

7.

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.

Prestipino A, Emhardt AJ, Aumann K, O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L, Vuckovic S, Boerries M, Busch H, Halbach S, Pennisi S, Poggio T, Apostolova P, Veratti P, Hettich M, Niedermann G, Bartholomä M, Shoumariyeh K, Jutzi JS, Wehrle J, Dierks C, Becker H, Schmitt-Graeff A, Follo M, Pfeifer D, Rohr J, Fuchs S, Ehl S, Hartl FA, Minguet S, Miething C, Heidel FH, Kröger N, Triviai I, Brummer T, Finke J, Illert AL, Ruggiero E, Bonini C, Duyster J, Pahl HL, Lane SW, Hill GR, Blazar BR, von Bubnoff N, Pearce EL, Zeiser R.

Sci Transl Med. 2018 Feb 21;10(429). pii: eaam7729. doi: 10.1126/scitranslmed.aam7729.

8.

A deep conical agarose microwell array for adhesion independent three-dimensional cell culture and dynamic volume measurement.

Thomsen AR, Aldrian C, Bronsert P, Thomann Y, Nanko N, Melin N, Rücker G, Follo M, Grosu AL, Niedermann G, Layer PG, Heselich A, Lund PG.

Lab Chip. 2017 Dec 19;18(1):179-189. doi: 10.1039/c7lc00832e.

9.

Mitochondrial Priming by CD28.

Klein Geltink RI, O'Sullivan D, Corrado M, Bremser A, Buck MD, Buescher JM, Firat E, Zhu X, Niedermann G, Caputa G, Kelly B, Warthorst U, Rensing-Ehl A, Kyle RL, Vandersarren L, Curtis JD, Patterson AE, Lawless S, Grzes K, Qiu J, Sanin DE, Kretz O, Huber TB, Janssens S, Lambrecht BN, Rambold AS, Pearce EJ, Pearce EL.

Cell. 2017 Oct 5;171(2):385-397.e11. doi: 10.1016/j.cell.2017.08.018. Epub 2017 Sep 14.

10.

Beyond checkpoint inhibition - Immunotherapeutical strategies in combination with radiation.

Eckert F, Gaipl US, Niedermann G, Hettich M, Schilbach K, Huber SM, Zips D.

Clin Transl Radiat Oncol. 2017 Feb 4;2:29-35. doi: 10.1016/j.ctro.2016.12.006. eCollection 2017 Feb. Review.

11.

Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications.

Popp I, Grosu AL, Niedermann G, Duda DG.

Radiother Oncol. 2016 Aug;120(2):185-94. doi: 10.1016/j.radonc.2016.07.013. Epub 2016 Aug 2. Review.

PMID:
27495145
12.
13.

High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers.

Hettich M, Braun F, Bartholomä MD, Schirmbeck R, Niedermann G.

Theranostics. 2016 Jun 18;6(10):1629-40. doi: 10.7150/thno.15253. eCollection 2016.

14.

Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing γ-Irradiation.

Hettich M, Lahoti J, Prasad S, Niedermann G.

Cancer Res. 2016 Aug 15;76(16):4673-83. doi: 10.1158/0008-5472.CAN-15-3451. Epub 2016 Jun 14.

15.

Imaging and Selective Elimination of Glioblastoma Stem Cells with Theranostic Near-Infrared-Labeled CD133-Specific Antibodies.

Jing H, Weidensteiner C, Reichardt W, Gaedicke S, Zhu X, Grosu AL, Kobayashi H, Niedermann G.

Theranostics. 2016 Apr 12;6(6):862-74. doi: 10.7150/thno.12890. eCollection 2016.

16.

Decrease of VEGF-A in myeloid cells attenuates glioma progression and prolongs survival in an experimental glioma model.

Osterberg N, Ferrara N, Vacher J, Gaedicke S, Niedermann G, Weyerbrock A, Doostkam S, Schaefer HE, Plate KH, Machein MR.

Neuro Oncol. 2016 Jul;18(7):939-49. doi: 10.1093/neuonc/now005. Epub 2016 Mar 6.

17.
18.

Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells.

Prasad S, Gaedicke S, Machein M, Mittler G, Braun F, Hettich M, Firat E, Klingner K, Schüler J, Wider D, Wäsch RM, Herold-Mende C, Elsässer-Beile U, Niedermann G.

Cancer Res. 2015 Jun 1;75(11):2166-76. doi: 10.1158/0008-5472.CAN-14-2415. Epub 2015 Apr 3.

19.

Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57.

Zhu X, Prasad S, Gaedicke S, Hettich M, Firat E, Niedermann G.

Oncotarget. 2015 Jan 1;6(1):171-84.

20.

Early-onset Evans syndrome, immunodeficiency, and premature immunosenescence associated with tripeptidyl-peptidase II deficiency.

Stepensky P, Rensing-Ehl A, Gather R, Revel-Vilk S, Fischer U, Nabhani S, Beier F, Brümmendorf TH, Fuchs S, Zenke S, Firat E, Pessach VM, Borkhardt A, Rakhmanov M, Keller B, Warnatz K, Eibel H, Niedermann G, Elpeleg O, Ehl S.

Blood. 2015 Jan 29;125(5):753-61. doi: 10.1182/blood-2014-08-593202. Epub 2014 Nov 20.

21.

FET-PET-based reirradiation and chloroquine in patients with recurrent glioblastoma: first tolerability and feasibility results.

Bilger A, Bittner MI, Grosu AL, Wiedenmann N, Meyer PT, Firat E, Niedermann G, Weber WA, Milanović D.

Strahlenther Onkol. 2014 Oct;190(10):957-61. doi: 10.1007/s00066-014-0693-2. Epub 2014 Jun 14.

PMID:
24928248
22.

Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells.

Gaedicke S, Braun F, Prasad S, Machein M, Firat E, Hettich M, Gudihal R, Zhu X, Klingner K, Schüler J, Herold-Mende CC, Grosu AL, Behe M, Weber W, Mäcke H, Niedermann G.

Proc Natl Acad Sci U S A. 2014 Feb 11;111(6):E692-701. doi: 10.1073/pnas.1314189111. Epub 2014 Jan 27.

23.
24.

Resistance to hypoxia-induced, BNIP3-mediated cell death contributes to an increase in a CD133-positive cell population in human glioblastomas in vitro.

Kahlert UD, Maciaczyk D, Dai F, Claus R, Firat E, Doostkam S, Bogiel T, Carro MS, Döbrössy M, Herold-Mende C, Niedermann G, Prinz M, Nikkhah G, Maciaczyk J.

J Neuropathol Exp Neurol. 2012 Dec;71(12):1086-99. doi: 10.1097/NEN.0b013e3182772d83.

PMID:
23147506
25.

Chloroquine or chloroquine-PI3K/Akt pathway inhibitor combinations strongly promote γ-irradiation-induced cell death in primary stem-like glioma cells.

Firat E, Weyerbrock A, Gaedicke S, Grosu AL, Niedermann G.

PLoS One. 2012;7(10):e47357. doi: 10.1371/journal.pone.0047357. Epub 2012 Oct 16.

26.

[The role of radiotherapy in the induction of antitumor immune responses].

Multhoff G, Gaipl US, Niedermann G.

Strahlenther Onkol. 2012 Nov;188 Suppl 3:312-5. doi: 10.1007/s00066-012-0206-0. Review. German. No abstract available.

PMID:
22907580
27.

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.

Milanović D, Braun F, Weber W, Grosu AL, Behe M, Niedermann G.

BMC Cancer. 2012 Jun 13;12:242. doi: 10.1186/1471-2407-12-242.

28.

Activation of canonical WNT/β-catenin signaling enhances in vitro motility of glioblastoma cells by activation of ZEB1 and other activators of epithelial-to-mesenchymal transition.

Kahlert UD, Maciaczyk D, Doostkam S, Orr BA, Simons B, Bogiel T, Reithmeier T, Prinz M, Schubert J, Niedermann G, Brabletz T, Eberhart CG, Nikkhah G, Maciaczyk J.

Cancer Lett. 2012 Dec 1;325(1):42-53. doi: 10.1016/j.canlet.2012.05.024. Epub 2012 May 28.

PMID:
22652173
29.

Delayed cell death associated with mitotic catastrophe in γ-irradiated stem-like glioma cells.

Firat E, Gaedicke S, Tsurumi C, Esser N, Weyerbrock A, Niedermann G.

Radiat Oncol. 2011 Jun 10;6:71. doi: 10.1186/1748-717X-6-71.

30.

The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells.

Brabletz S, Bajdak K, Meidhof S, Burk U, Niedermann G, Firat E, Wellner U, Dimmler A, Faller G, Schubert J, Brabletz T.

EMBO J. 2011 Feb 16;30(4):770-82. doi: 10.1038/emboj.2010.349. Epub 2011 Jan 11.

31.

Non-invasive in vivo imaging of tumor-associated CD133/prominin.

Tsurumi C, Esser N, Firat E, Gaedicke S, Follo M, Behe M, Elsässer-Beile U, Grosu AL, Graeser R, Niedermann G.

PLoS One. 2010 Dec 20;5(12):e15605. doi: 10.1371/journal.pone.0015605.

32.

Molecular radiobiology meets clinical radiation oncology.

Firat E, Heinemann F, Grosu AL, Hermann F, Niedermann G.

Int J Radiat Biol. 2010 Mar;86(3):252-9. doi: 10.3109/09553000903419320.

PMID:
20201653
33.

Viability and DNA damage responses of TPPII-deficient Myc- and Ras-transformed fibroblasts.

Tsurumi C, Firat E, Gaedicke S, Huai J, Mandal PK, Niedermann G.

Biochem Biophys Res Commun. 2009 Sep 4;386(4):563-8. doi: 10.1016/j.bbrc.2009.06.068. Epub 2009 Jun 17.

PMID:
19539606
34.

IRAP identifies an endosomal compartment required for MHC class I cross-presentation.

Saveanu L, Carroll O, Weimershaus M, Guermonprez P, Firat E, Lindo V, Greer F, Davoust J, Kratzer R, Keller SR, Niedermann G, van Endert P.

Science. 2009 Jul 10;325(5937):213-7. doi: 10.1126/science.1172845. Epub 2009 Jun 4.

35.

Tripeptidyl peptidase II plays a role in the radiation response of selected primary cell types but not based on nuclear translocation and p53 stabilization.

Firat E, Tsurumi C, Gaedicke S, Huai J, Niedermann G.

Cancer Res. 2009 Apr 15;69(8):3325-31. doi: 10.1158/0008-5472.CAN-08-3269. Epub 2009 Apr 7.

36.

Activation of cellular death programs associated with immunosenescence-like phenotype in TPPII knockout mice.

Huai J, Firat E, Nil A, Million D, Gaedicke S, Kanzler B, Freudenberg M, van Endert P, Kohler G, Pahl HL, Aichele P, Eichmann K, Niedermann G.

Proc Natl Acad Sci U S A. 2008 Apr 1;105(13):5177-82. doi: 10.1073/pnas.0801413105. Epub 2008 Mar 24.

37.

Analysis of direct and cross-presentation of antigens in TPPII knockout mice.

Firat E, Huai J, Saveanu L, Gaedicke S, Aichele P, Eichmann K, van Endert P, Niedermann G.

J Immunol. 2007 Dec 15;179(12):8137-45.

38.

Inducible gene expression with the Tet-on system in CD4+ T cells and thymocytes of mice.

Huai J, Firat E, Niedermann G.

Genesis. 2007 Jul;45(7):427-31.

PMID:
17603790
39.

The role of endoplasmic reticulum-associated aminopeptidase 1 in immunity to infection and in cross-presentation.

Firat E, Saveanu L, Aichele P, Staeheli P, Huai J, Gaedicke S, Nil A, Besin G, Kanzler B, van Endert P, Niedermann G.

J Immunol. 2007 Feb 15;178(4):2241-8.

40.

Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.

Hildenbrand B, Sauer B, Kalis O, Stoll C, Freudenberg MA, Niedermann G, Giesler JM, Jüttner E, Peters JH, Häring B, Leo R, Unger C, Azemar M.

Prostate. 2007 Apr 1;67(5):500-8.

PMID:
17262804
41.

Identification of naturally processed HLA-A2--restricted proinsulin epitopes by reverse immunology.

Hassainya Y, Garcia-Pons F, Kratzer R, Lindo V, Greer F, Lemonnier FA, Niedermann G, van Endert PM.

Diabetes. 2005 Jul;54(7):2053-9.

42.

Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy.

Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S.

J Immunol. 2005 Jun 15;174(12):8210-8.

43.

Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum.

Saveanu L, Carroll O, Lindo V, Del Val M, Lopez D, Lepelletier Y, Greer F, Schomburg L, Fruci D, Niedermann G, van Endert PM.

Nat Immunol. 2005 Jul;6(7):689-97. Epub 2005 May 22.

PMID:
15908954
44.
45.

Differential proteasomal processing of hydrophobic and hydrophilic protein regions: contribution to cytotoxic T lymphocyte epitope clustering in HIV-1-Nef.

Lucchiari-Hartz M, Lindo V, Hitziger N, Gaedicke S, Saveanu L, van Endert PM, Greer F, Eichmann K, Niedermann G.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7755-60. Epub 2003 Jun 16.

46.

Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.

Gaedicke S, Firat-Geier E, Constantiniu O, Lucchiari-Hartz M, Freudenberg M, Galanos C, Niedermann G.

Cancer Res. 2002 Dec 1;62(23):6901-8.

47.

Immunological functions of the proteasome.

Niedermann G.

Curr Top Microbiol Immunol. 2002;268:91-136. Review.

PMID:
12083010
48.
49.

Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.

Lucchiari-Hartz M, van Endert PM, Lauvau G, Maier R, Meyerhans A, Mann D, Eichmann K, Niedermann G.

J Exp Med. 2000 Jan 17;191(2):239-52.

50.

The specificity of proteasomes: impact on MHC class I processing and presentation of antigens.

Niedermann G, Geier E, Lucchiari-Hartz M, Hitziger N, Ramsperger A, Eichmann K.

Immunol Rev. 1999 Dec;172:29-48. Review.

PMID:
10631935

Supplemental Content

Loading ...
Support Center